News - Novartis, Anti-virals

Filter

Current filters:

NovartisAnti-virals

Popular Filters

MSF warns of US/Indian tension over generic policy discussion

MSF warns of US/Indian tension over generic policy discussion

25-09-2013

Humanitarian group Médecins Sans Frontières has warned that India is facing political pressure from…

Anti-viralsAsia-PacificBayerGenericsGleevecHealthcareNexavarNorth AmericaNovartisPolitics

Switzerland's Lonza involvement in South Africa pharma project in doubt

28-05-2013

The South Africa government is expected to publish a request for information from potential international,…

Anti-viralsGenericsLonzaNovartisProductionRest of the World

News briefs: Novartis drops Ruvise MAA; B-MS settlement; Germany donates to Global Fund

25-01-2013

The European Medicines Agency says it has been formally notified by Swiss drug major Novartis (NOVN:…

Anti-viralsBMS-986094Bristol-Myers SquibbFinancialLegalNovartisPharmaceuticalRare diseasesRegulationRuviseTropical diseases

UK's NICE issues draft guideline for diagnosis and management of hepatitis B

17-01-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) is currently developing…

Anti-viralsBaracludeBiotechnologyBristol-Myers SquibbEuropeGilead SciencesNovartisPharmaceuticalPreveonPricingRegulationSebivoViread

Clinical briefs from Novartis, Gilead and AstraZeneca

13-11-2012

Swiss drug major Novartis (NOVN: VX) has released new two-year results from the largest Phase III study…

ACZ885Anti-Arthritics/RheumaticsAnti-viralsAstraZenecaBiotechnologyCerticanGilead SciencesnaloxegolNeurologicalNovartisPharmaceuticalResearchsofosbuvir

Novartis restructures deal with Idenix Pharmaceuticals

01-08-2012

USA-based Idenix Pharmaceuticals (Nasdaq: IDIX) says that Swiss drug major Novartis (NOVN: VX) has restructured…

Anti-viralsIdenix PharmaceuticalsLicensingNovartisPharmaceuticaltelbivudine

Novartis makes Tekturna label change, updates on Gilenya and stops alisporivir trial

20-04-2012

In a day of mixed news for the Swiss drug major, Novartis (NOVN: VX) said yesterday that it has updated…

alisporivirAnti-viralsCardio-vascularGilenyaNeurologicalNovartisPharmaceuticalRegulationResearchTekturna

Positive NICE news for Gilenya for MS and Incivo for hep C

16-03-2012

There was good news from the UK drugs watchdog the Institute for Health and Clinical Excellence (NICE)…

Anti-viralsEuropeGilenyaIncivoJanssen-CilagJohnson & JohnsonNeurologicalNovartisPharmaceuticalPricingRegulation

Enanta Pharma in $440 HCV licensing deal with Novartis

22-02-2012

USA-based discovery and development company Enanta Pharmaceuticals yesterday signed an exclusive collaboration…

Anti-viralsEnanta PharmaceuticalsLicensingNovartisPharmaceutical

EMA recommends new Rxing info on Victrelis and warnings for aliskiren

20-02-2012

The European Medicines Agency has recommended updating the prescribing information for US drug giant…

Aliskiren TabletsAnti-viralsCardio-vascularEuropeMerck & CoNovartisPharmaceuticalRasilezRegulationTekturnaVictrelis

European Commission OKs Novartis’ Rasitrio and new label for Bristol-Myers’ Reyataz

28-11-2011

Following a positive advisory recommendation in September, the European Commission has now approved Swiss…

Anti-viralsBristol-Myers SquibbCardio-vascularEuropeNovartisPharmaceuticalRasitrioRegulationReyataz

Novartis’ alisporivir may become first interferon-free oral for hepatitis C G2/G3

14-11-2011

The clear conclusion from a clinical trial of alisporivir (DEB025, from Swiss drug major Novartis [NOVN:…

alisporivirAnti-viralsDebiopharmNovartisPharmaceuticalResearch

Back to top